Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients
Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients
复制标题
DOI：
10.1016/j.cmi.2016.02.002
复制
发表时间：
2016-06-01
影响因子：
14.2
通讯作者：
Janssen, H. L. A.
中科院分区：
文献类型：
--
作者：
van Campenhout, M. J. H.;Brouwer, W. P.;Janssen, H. L. A.
乙型肝炎核心相关抗原（HBcrAg）是一种新的血清标志物，可用于监测慢性乙型肝炎感染。在175例接受恩替卡韦（ETV）联合或不联合聚乙二醇干扰素（PEG-IFN）治疗的乙型肝炎e抗原阳性患者中测量HBcrAg。有联合缓解的患者与无联合缓解的患者HBcrAg下降更明显(ETV: -3.22 vs -1.71 log U/mL, p
Hepatitis B core-related antigen (HBcrAg), a new serum marker, may be useful in monitoring chronic hepatitis B infection. HBcrAg was measured in 175 hepatitis B e antigen-positive patients treated with entecavir (ETV) with or without peginterferon (PEG-IFN) add-on therapy. Decline in HBcrAg was stronger in patients with vs. without combined response (ETV: -3.22 vs. -1.71 log U/mL, p